1. Introduction {#sec1-marinedrugs-15-00374}
===============

Historically, natural products have inspired the development of many pharmaceuticals and agrochemicals, which, have in turn, played an important role in improving human and animal health and agricultural productivity, enhancing the quality of life for communities across the globe \[[@B1-marinedrugs-15-00374]\]. One of the defining characteristics of natural products is their structure diversity, which can encompass complex carbocyclic and heterocyclic scaffolds, annotated with a wide array of functional groups and stereochemical features. As such, even a limited set of biosynthetic precursors can deliver remarkable chemical diversity. Illustrative of this phenomenon are bromophenols from marine red algae (Rhodophyta) \[[@B2-marinedrugs-15-00374],[@B3-marinedrugs-15-00374],[@B4-marinedrugs-15-00374],[@B5-marinedrugs-15-00374],[@B6-marinedrugs-15-00374],[@B7-marinedrugs-15-00374],[@B8-marinedrugs-15-00374],[@B9-marinedrugs-15-00374],[@B10-marinedrugs-15-00374],[@B11-marinedrugs-15-00374],[@B12-marinedrugs-15-00374],[@B13-marinedrugs-15-00374],[@B14-marinedrugs-15-00374],[@B15-marinedrugs-15-00374],[@B16-marinedrugs-15-00374],[@B17-marinedrugs-15-00374],[@B18-marinedrugs-15-00374],[@B19-marinedrugs-15-00374],[@B20-marinedrugs-15-00374]\]. For example, the red alga *Symphyocladia latiuscula* (Harvey) Yamada has been reported to produce a diverse array of bromophenols elaborated by sulfoxides, sulphones, sulfates, glutamines, pyrrolidin-2-ones, ureas, diketopiperazines, and aconitic acids, with biological properties spanning antibacterial \[[@B11-marinedrugs-15-00374],[@B12-marinedrugs-15-00374]\], antifungal \[[@B10-marinedrugs-15-00374],[@B11-marinedrugs-15-00374],[@B12-marinedrugs-15-00374],[@B13-marinedrugs-15-00374],[@B14-marinedrugs-15-00374]\], antiviral \[[@B15-marinedrugs-15-00374]\], anticancer \[[@B16-marinedrugs-15-00374]\], free radical scavenging \[[@B9-marinedrugs-15-00374],[@B17-marinedrugs-15-00374],[@B18-marinedrugs-15-00374]\], aldose reductase inhibitory \[[@B19-marinedrugs-15-00374]\], and Taq DNA polymerase inhibitory activities \[[@B20-marinedrugs-15-00374]\]. *S. latiuscula* bromophenols typically contain at least one 2,3,6-tribromo-4,5-dihydroxybenzyl moiety, as consistent with a highly conserved biosynthetic pathway. This report described our efforts to further elaborate the chemical diversity of *S. latiuscula*.

2. Results and Discussion {#sec2-marinedrugs-15-00374}
=========================

The EtOAc extract of a Chinese collection of *S. latiuscula* was concentrated *in vacuo* and subjected to a sequence of normal, reversed phase, and gel chromatography, with HPLC-MS analysis being used to prioritize fractions of interest. Following this strategy, we isolated and characterized six citric acid derived natural products, aconitates A--F (**1**--**6**), together with two known and ten new polybrominated phenol adducts, symphyocladins C/D (**7a/b**), and symphyocladins H--Q (**8a/b**, **9a/b** and **10**--**15**), respectively ([Figure 1](#marinedrugs-15-00374-f001){ref-type="fig"}). A spectroscopic analysis approach (see [Table 1](#marinedrugs-15-00374-t001){ref-type="table"}, [Table 2](#marinedrugs-15-00374-t002){ref-type="table"}, [Table 3](#marinedrugs-15-00374-t003){ref-type="table"}, [Table 4](#marinedrugs-15-00374-t004){ref-type="table"} and [Table 5](#marinedrugs-15-00374-t005){ref-type="table"}) to the structure elucidation of all of these metabolites is summarized below.

HRESI(+)MS measurements confirmed that **1** (C~7~H~8~O~6~, Δmmu +0.2), **2** (C~7~H~8~O~6~, Δmmu +0.1) and **3** (C~7~H~8~O~6~, Δmmu +0.1) were isomeric, while analysis of the one-dimensional (1D) and two-dimensional (2D) NMR (methanol-*d*~4~) data ([Figures S8--S13](#app1-marinedrugs-15-00374){ref-type="app"}, [Tables S2 and S3](#app1-marinedrugs-15-00374){ref-type="app"}) suggested they were mono methyl esters of *E*-aconitic acid, for which we attribute the trivial names aconitates A--C. Assignment of *E* ∆^3,4^ configurations were inferred from diagnostic chemical shifts for H-4 and C-2 in **1** (δ~H~ 6.92; δ~C~ 33.8), **2** (δ~H~ 6.89; δ~C~ 33.9), and **3** (δ~H~ 6.91; δ~C~ 33.9), when compared to the authentic standards for *E* (δ~H~ 6.90; δ~C~ 33.8) and *Z* (δ~H~ 6.26; δ~C~ 40.2) aconitic acid ([Figures S1--S7](#app1-marinedrugs-15-00374){ref-type="app"}, [Table S1](#app1-marinedrugs-15-00374){ref-type="app"}). HMBC correlations permitted assignment of the methyl ester regiochemistry across **1**--**3** with correlations from (i) the OMe (δ~H~ 3.67) and H~2~-2 (δ~H~ 3.89) to C-1 (δ~C~ 172.7) confirming a C-1 CO~2~Me in aconitate A (**1**), (ii) the OMe (δ~H~ 3.81) and H~2~-2 (δ~H~ 3.89) to C-6 (δ~C~ 168.4) confirming a C-6 CO~2~Me in aconitate B (**2**), and (iii) the OMe (δ~H~ 3.77) and H-4 (δ~H~ 6.91) to C-5 (δ~C~ 167.5) confirming a C-5 CO~2~Me in aconitate C (**3**) ([Figure 2](#marinedrugs-15-00374-f002){ref-type="fig"}).

HRESI(+)MS measurements suggested that **4** (C~8~H~10~O~6~, Δmmu +0.2) and **5** (C~8~H~10~O~6~, Δmmu +0.2) were isomeric dimethyl esters, and **6** (C~9~H~12~O~6~, Δmmu +0.1) was a trimethyl ester, of aconitic acid. Analysis of the NMR (methanol-*d*~4~) data for **4**--**6** ([Figures S14--S19](#app1-marinedrugs-15-00374){ref-type="app"}, [Tables S3 and S4](#app1-marinedrugs-15-00374){ref-type="app"}) confirmed these assignments, with *E* ∆^3,4^ configurations being inferred from diagnostic chemical shifts for H-4 and C-2 in aconitate D (**4**) (δ~H~ 6.91; δ~C~ 33.8), aconitate E (**5**) (δ~H~ 6.92; δ~C~ 33.9) and aconitate F (**6**) (δ~H~ 6.92; δ~C~ 33.8), and HMBC correlations permitting the assignment of the dimethyl ester regiochemistry across **4** and **5**. For example, correlations from an OMe (δ~H~ 3.67) and H~2~-2 (δ~H~ 3.91) to C-1 (δ~C~ 172.5), and from an OMe (δ~H~ 3.80) and H~2~-2 to C-6 (δ~C~ 168.2), confirmed the presence of C-1 CO~2~Me and C-6 CO~2~Me moieties in **4**, whereas correlations from an OMe (δ~H~ 3.67) and H~2~-2 (δ~H~ 3.91) to C-1 (δ~C~ 172.5), and from an OMe (δ~H~ 3.76) and H-4 (δ~H~ 6.92) to C-5 (δ~C~ 167.5), confirmed C-1 CO~2~Me and C-5 CO~2~Me moieties in **5** ([Figure 2](#marinedrugs-15-00374-f002){ref-type="fig"}).

HRESI(+)MS measurements confirmed that **7a/b** (C~14~H~11~Br~3~O~8~, Δmmu +0.5) and **8a/b** (C~14~H~11~Br~3~O~8~, ∆mmu +0.4) were isomeric, and suggested that **9a/b** (C~15~H~13~Br~3~O~8~, Δmmu +0.4) and **10** (C~15~H~13~Br~3~O~8~, Δmmu +0.5) were CH~2~ homologues, and **11** (C~17~H~17~Br~3~O~8~, Δmmu +0.6) was a CH~2~CH~2~ homologue of **7a/b** and **8a/b**. Analysis of the NMR (acetone-*d*~6~) data for **7a/b** ([Figures S20 and S21](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 1](#marinedrugs-15-00374-t001){ref-type="table"}, [Table 2](#marinedrugs-15-00374-t002){ref-type="table"} and [Table S5](#app1-marinedrugs-15-00374){ref-type="app"}) confirmed them as symphyocladins C/D, first reported in 2012 from *S. latiuscula* as an inseparable mixture of *Z/E* ∆^2,7′^ isomers \[[@B13-marinedrugs-15-00374]\]. Analysis of the NMR (methanol-*d*~4~) data for symphyocladins H/I (**8a/b**) ([Figures S22--S27](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 1](#marinedrugs-15-00374-t001){ref-type="table"}, [Table 2](#marinedrugs-15-00374-t002){ref-type="table"} and [Table S6](#app1-marinedrugs-15-00374){ref-type="app"}) revealed ∆^2,3^ and C-5 CO~2~Me moieties, as evidenced by diagnostic HMBC correlations ([Figure 3](#marinedrugs-15-00374-f003){ref-type="fig"}). Significantly, these data also revealed an interconverting mixture of *E/Z* ∆^2,3^ isomers, in which the minor *Z* isomer, symphyocladin H (**8a**), as evidenced by a ROESY correlation between H~2~-4 and H~2~-7′ ([Figure 3](#marinedrugs-15-00374-f003){ref-type="fig"}), was in equilibrium with the major *E* isomer, symphyocladin I (**8b**). Further analysis of this NMR data revealed chemical shift differences diagnostic for ∆^2,3^ geometric isomers; H~2~-4 (*E* δ~H~ 3.65, δ~C~ 35.0; *Z* δ~H~ 3.19, δ~C~ 29.5), C-1 (*E* δ~C~ 170.3; *Z* δ~C~ 166.5), C-3 (*E* δ~C~ 127.4; *Z* δ~C~ 137.8), and C-5 CO~2~Me (*E* δ~H~ 3.71; *Z* δ~H~ 3.51). Remarkably, the NMR (acetonitrile-*d*~3~) data for **8a/b** revealed a single *Z* isomer **8a**, as evidenced by simplified spectra, a ROESY correlation between H~2~-4 and H~2~-7′, and diagnostic chemical shifts ([Figures S28 and S29](#app1-marinedrugs-15-00374){ref-type="app"}, [Table S7](#app1-marinedrugs-15-00374){ref-type="app"}). We speculate that in aprotic solvents (i.e., acetonitrile-*d*~3~), hydrogen bonding between adjacent CO~2~H moieties exclusively favors the lower energy *Z* ∆^2,3^ isomer. By contrast, in protic solvents (i.e., methanol-*d*~4~), the disruption of this hydrogen bonding favor equilibration to an *E/Z* ∆^2,3^ mixture dominated by the less sterically constrained *E* isomer. This observation highlights the critical importance that NMR solvents can play in the analysis and structure elucidation of natural products.

Analysis of the NMR (DMSO-*d*~6~) data for symphyocladins J/K (**9a/b**) ([Figures S30 and S31](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 1](#marinedrugs-15-00374-t001){ref-type="table"}, [Table 2](#marinedrugs-15-00374-t002){ref-type="table"} and [Table S8](#app1-marinedrugs-15-00374){ref-type="app"}) identified an inseparable mixture of C-6 CO~2~Me homologues of **7a/b** and **8a/b**, as evidenced by spectroscopic comparisons and diagnostic HMBC correlations from the additional CO~2~[Me]{.ul} resonances to C-6 ([Figure 3](#marinedrugs-15-00374-f003){ref-type="fig"}). In this instance, as hydrogen bonding does not stabilize double bond isomers, the *Z/E* mixture prevails even in an aprotic solvent (i.e., DMSO-*d*~6~). Analysis of the NMR (acetone-*d*~6~) data for symphyocladin L (**10**) ([Figures S32 and S33](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 3](#marinedrugs-15-00374-t003){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S9](#app1-marinedrugs-15-00374){ref-type="app"}) revealed a ∆^3,4^ isomer and 1-CO~2~Me homologue of **7a/b** and **8a/b**, as evidenced by COSY correlations between H-2 and H~2~-7′, and diagnostic HMBC correlations positioning both C-1 CO~2~Me and C-5 CO~2~Me ([Figure 3](#marinedrugs-15-00374-f003){ref-type="fig"}). The structure of **10** inclusive of an *E* ∆^3,4^ configuration and its racemic nature were confirmed by single crystal X-ray analysis with the compound crystallizing in a centrosymmetric space group ([Figures S34 and S35](#app1-marinedrugs-15-00374){ref-type="app"}). Analysis of the NMR (methanol-*d*~4~) data for symphyocladin M (**11**) ([Figures S36 and S37](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 3](#marinedrugs-15-00374-t003){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S10](#app1-marinedrugs-15-00374){ref-type="app"}) revealed it as a C-6 CO~2~Et homologue of **10**, as evidenced by spectroscopic comparisons and an HMBC correlation from the CO~2~[Et]{.ul} moiety to C-6.

HRESI(+)MS measurements suggested that **12** (C~13~H~11~Br~3~O~6~, Δmmu +0.5) was a decarboxy analogue of **7a/b** and **8a/b**; **13** (C~14~H~13~Br~3~O~7~, Δmmu +0.5) was a dihydro oxidized methyl ester of **12**; **14** (C~13~H~11~Br~3~O~6~, Δmmu +0.5) was a decarboxymethyl analogue of **10**; and, **15** (C~14~H~13~Br~3~O~6~, Δmmu +0.5) was a CH~2~ homologue of **14**. Comparison of the NMR (methanol-*d*~4~) data for symphyocladin N (**12**) ([Figures S38 and S39](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 4](#marinedrugs-15-00374-t004){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S11](#app1-marinedrugs-15-00374){ref-type="app"}) with that for **8a/b** revealed the key difference as replacement of the C-1 CO~2~H moiety in **8a/b** with an H-2 olefinic methine (δ~H~ 6.79) coupled to H~2~-7′ (δ~H~ 4.05). The presence of a C-5 CO~2~Me moiety in **12** was evident from an HMBC correlation from the OMe (δ~H~ 3.66) to C-5 (δ~C~ 171.3), while an *E* Δ^2,3^ configuration was confirmed by a ROESY correlation between H~2~-4 (δ~H~ 3.60) and H~2~-7′ ([Figure 4](#marinedrugs-15-00374-f004){ref-type="fig"}). Analysis of the NMR (methanol-*d*~4~) data for symphyocladin O (**13**) ([Figures S40 and S41](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 4](#marinedrugs-15-00374-t004){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"}, and [Table S12](#app1-marinedrugs-15-00374){ref-type="app"}) revealed it to be a saturated oxidized analogue of **12**, as evidenced by COSY correlations between a diastereotopic H~2~-2 (δ~H~ 3.35/3.27), through H-3 (δ~H~ 3.34) to a diastereotopic H~2~-4 (δ~H~ 2.86/2.73). Likewise, replacement of the C-7′ sp^3^ methylene in **12** (δ~C~ 39.0) with a carbonyl resonance in 13 (δ~C~ 202.2) was evidence of a 7-oxo moiety. Diagnostic HMBC correlations also established the presence of incorporated C-5 CO~2~[Me]{.ul} (δ~H~ 3.68) and C-6 CO~2~[Me]{.ul} (δ~H~ 3.71) moieties (see [Figure 3](#marinedrugs-15-00374-f003){ref-type="fig"}).

Comparison of the NMR (methanol-*d*~4~) data for symphyocladin P (**14**) ([Figures S42 and S43](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 4](#marinedrugs-15-00374-t004){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S13](#app1-marinedrugs-15-00374){ref-type="app"}) with that for **10** revealed the key difference as replacement of the C-5 CO~2~Me moiety in **10** with a diastereotopic H~2~-4 olefinic methylene (δ~H~ 6.22/5.44). Comparison of the NMR (acetone-*d*~6~) data for symphyocladin Q (**15**) ([Figures S44 and S45](#app1-marinedrugs-15-00374){ref-type="app"}, [Table 4](#marinedrugs-15-00374-t004){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S14](#app1-marinedrugs-15-00374){ref-type="app"}) with that for **14** revealed the key difference as an additional resonance, attributed to a C-6 CO~2~[Me]{.ul} moiety (δ~H~ 3.71). Structure assignments for **14** and **15** were further supported by diagnostic 2D NMR correlations ([Figure 4](#marinedrugs-15-00374-f004){ref-type="fig"}).

Structural similarities across **1**--**15** suggest a highly conserved biosynthesis. Building on this observation, we propose a biosynthetic relationship ([Figure 5](#marinedrugs-15-00374-f005){ref-type="fig"}), in which the aconitates A--F (**1**--**6**) are viewed as mono, di, and tri methyl esters of the precursor *E*-aconitic acid, itself a dehydration product of citric acid. Likewise, metabolites **7**--**15** can be viewed as adducts between aconitates and an intermediate quinone methide that is generated from 2,3,6-tribromo-4,5-dihydroxybenzyl alcohol, further elaborated by a combination of 1,3-hydride shifts, decarboxylations and oxidations. Although **7a/b**, **9a/b**, **10**--**11,** and **13** incorporate a single chiral sp^3^ center, as they do not exhibit measurable optical rotations they are presumed to be racemic, as confirmed for **10** by X-ray crystallography. The absence of double bond migrations (i.e., racemization) during isolation and handling suggests that this racemic character is a function of achiral adduct addition. The proposed biosynthetic relationship informs a possible biomimetic synthesis of **7**--**15**, although, in our hands, synthetic 2,3,6-tribromo-4,5-dihydroxybenzyl alcohol proved stable to both acid and base conditions indicative of a requirement to activate the benzyl alcohol moiety to effect dehydration and the formation of a quinone methide.

3. Materials and Methods {#sec3-marinedrugs-15-00374}
========================

**General Experimental Procedures.** Specific optical rotations (\[α\]~D~) were measured on a polarimeter in a 100 × 2 mm cell at 22 °C. NMR spectra were obtained on a Bruker Avance DRX600 or DRX500 spectrometers, in the solvents indicated and referenced to residual ^1^H and ^13^C signals in deuterated solvents. Electrospray ionization mass spectra (ESIMS) were acquired using an Agilent 1100 Series separations module equipped with an Agilent 1100 Series LC/MSD mass detector in both positive and negative ion modes. High-resolution ESIMS measurements were obtained on a Bruker micrOTOF mass spectrometer by direct infusion in MeCN at 3 mL/min using sodium formate clusters as an internal calibrant. HPLC was performed using an Agilent 1100 Series separations module equipped with Agilent 1100 Series diode array and/or multiple wavelength detectors and Agilent 1100 Series fraction collector, controlled using ChemStation Rev.B02.01 and Purify version A.1.2 software.

**Algal material.** *Symphyocladia latiuscula* was collected on the coast of Qingdao, Shandong Province, China, in May 2004. The specimen identification was verified by Dr. Kui-Shuang Shao (Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, China). A voucher specimen (No. 2004X16) was deposited at the Herbarium of the Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, China.

**Extraction and isolation.** The air-dried red alga *Symphyocladia latiuscula* (4.3 kg) was extracted with 95% EtOH at room temperature (3 × 72 h). After the solvent was removed under reduced pressure at \<40 °C, a dark residue (610 g) was obtained. The residue was partitioned between EtOAc and H~2~O, and the EtOAc-soluble partition (320 g) was chromatographed over silica gel, eluting with a gradient of 0--100% Me~2~CO/petroleum ether to yield 85 fractions (F1--F85) (see [Supporting Information Scheme S1](#app1-marinedrugs-15-00374){ref-type="app"} for the fractionation scheme). Fraction F54 was further fractionated over Sephadex LH-20 using CHCl~3~--MeOH (2:1) to afford 21 fractions.

The sixth fraction from Sephadex LH-20 chromatography was fractionated on an ODS column, eluted by a stepwise gradient (0--100% MeOH/H~2~O) to afford 11 fractions. The third fraction was subjected to HPLC separation (Zorbax Eclipse XDB-C~8~, 5 μm, 250 × 9.4 mm column, 3.0 mL/min, gradient elution from 10 to 80% MeCN/H~2~O over 15 min, with isocratic 0.01% TFA modifier) to yield **1**--**6**; the sixth fraction was subjected to HPLC separation (Zorbax SB-C~18~, 5 μm, 250 × 9.4 mm column, 3.0 mL/min, gradient elution from 30 to 75% MeCN/H~2~O over 14 min, with isocratic 0.01% TFA modifier) to yield **8a/b** and **9a/b**; and the seventh fraction was subjected to HPLC separation (Zorbax Eclipse XDB-C~8~, 5 μm, 250 × 9.4 mm column, 3.0 mL/min, gradient elution from 40 to 55% MeCN/H~2~O over 20 min, with isocratic 0.01% TFA modifier) to yield **11** and **13**.

The seventh fraction from Sephadex LH-20 chromatography was subjected to HPLC fractionation (Zorbax SB-C~18~, 5 um, 250 × 9.4 mm column, 3.0 mL/min, gradient elution from 30 to 80% MeCN/H~2~O over 14 min, with isocratic 0.01% TFA modifier) to yield **10**.

The eighth fraction from Sephadex LH-20 chromatography was fractionated on an ODS column, eluted with a stepwise gradient (0--100% MeOH/H~2~O) to afford 11 fractions; the sixth fraction was subjected to HPLC fractionation (Zorbax SB-C~18~, 5 δm, 250 × 9.4 mm column, 3.0 mL/min, gradient elution from 35 to 50% MeCN/H~2~O over 15 min, with isocratic 0.01% TFA modifier) to yield **14**; the seventh fraction was subjected to HPLC fractionation (Zorbax SB-C~18~, 5 μm, 250 × 9.4 mm column, 3.0 mL/min, gradient elution from 50 to 60% MeCN/H~2~O over 12 min, with isocratic 0.01% TFA modifier) to yield **12** and **15**.

The ninth fraction from Sephadex LH-20 chromatography was fractionated on an ODS column, eluted with a stepwise gradient (0--100% MeOH/H~2~O) to afford 11 fractions; the third fraction was subjected to HPLC fractionation (Zorbax SB-C~18~, 5 μm, 250 × 9.4 mm column, 3.0 mL/min, gradient elution from 30 to 80% MeCN/H~2~O over 20 min, with isocratic 0.01% TFA modifier) to yield **7a/b**.

*Aconitate A* (**1**): White solid; NMR (600 MHz, methanol-*d*~4~) see [Table S2](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 189.0396 \[M + H\]^+^ (calcd. for C~7~H~8~O~6~ 189.0394).

*Aconitate B* (**2**): White solid; NMR (600 MHz, methanol-*d*~4~) see [Table S2](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 189.0395 \[M + H\]^+^ (calcd. for C~7~H~8~O~6~ 189.0394).

*Aconitate C* (**3**): White solid; NMR (600 MHz, methanol-*d*~4~) see [Table S3](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 189.0395 \[M + H\]^+^ (calcd. for C~7~H~8~O~6~ 189.0394).

*Aconitate D* (**4**): White solid; NMR (600 MHz, methanol-*d*~4~) see [Table S3](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 203.0552 \[M + H\]^+^ (calcd. for C~8~H~11~O~6~, 203.0550)

*Aconitate E* (**5**): White solid; NMR (600 MHz, methanol-*d*~4~) see [Table S4](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 203.0551 \[M + H\]^+^ (calcd. for C~8~H~11~O~6~, 203.0550).

*Aconitate F* (**6**): White solid; NMR (600 MHz, methanol-*d*~4~) see [Table S4](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 217.0708 \[M + H\]^+^ (calcd. for C~9~H~13~O~6~, 217.0707).

*Symphyocladins C/D* (**7a/b**): Light brown solid; NMR (600 MHz, acetone-*d*~6~) see [Table 1](#marinedrugs-15-00374-t001){ref-type="table"}, [Table 2](#marinedrugs-15-00374-t002){ref-type="table"} and [Table S5](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 544.8082 \[M + H\]^+^ (calcd. for C~14~H~12~Br~3~O~8~, 544.8077).

*Symphyocladins H/I* (**8a/b**): Light brown solid; NMR (600 MHz, methanol-*d*~4~, acetonitrile-*d*~3~) see [Table 1](#marinedrugs-15-00374-t001){ref-type="table"}, [Table 2](#marinedrugs-15-00374-t002){ref-type="table"}, [Tables S6 and S7](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 544.8081 \[M + H\]^+^ (calcd. for C~14~H~12~Br~3~O~8~, 544.8077).

*Symphyocladins J/K* (**9a/b**): Light brown solid; NMR (600 MHz, DMSO-*d*~6~) see [Table 1](#marinedrugs-15-00374-t001){ref-type="table"}, [Table 2](#marinedrugs-15-00374-t002){ref-type="table"} and [Table S8](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 558.8237 \[M + H\]^+^ (calcd. for C~15~H~14~Br~3~O~8~, 558.8233).

*Symphyocladin L* (**10**): Light brown solid; NMR (600 MHz, acetone-*d*~6~) see [Table 3](#marinedrugs-15-00374-t003){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S9](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 558.8238 \[M + H\]^+^ (calcd. for C~15~H~14~Br~3~O~8~, 558.8233).

*Symphyocladin M* (**11**): Light brown solid; NMR (600 MHz, methanol-*d*~4~) see [Table 3](#marinedrugs-15-00374-t003){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S10](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 586.8552 \[M + H\]^+^ (calcd. for C~17~H~17~Br~3~O~8~, 586.8546).

*Symphyocladin N* (**12**): Light brown solid; NMR (600 MHz, acetone-*d*~6~) see [Table 4](#marinedrugs-15-00374-t004){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S11](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 500.8184 \[M + H\]^+^ (calcd. for C~13~H~12~Br~3~O~6~, 500.8179).

*Symphyocladin O* (**13**): Light brown solid; NMR (600 MHz, methanol-*d*~4~) see [Table 4](#marinedrugs-15-00374-t004){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S12](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 530.8289 \[M + H\]^+^ (calcd. for C~14~H~14~Br~3~O~7~, 530.8284).

*Symphyocladin P* (**14**): Light brown solid; NMR (600 MHz, methanol-*d*~4~) see [Table 4](#marinedrugs-15-00374-t004){ref-type="table"}, [Table 5](#marinedrugs-15-00374-t005){ref-type="table"} and [Table S13](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 500.8184 \[M + H\]^+^ (calcd. for C~13~H~12~Br~3~O~6~, 500.8179).

*Symphyocladin Q* (**15**): Light brown solid; NMR (600 MHz, acetone-*d*~6~) see [Table 3](#marinedrugs-15-00374-t003){ref-type="table"}, [Table 4](#marinedrugs-15-00374-t004){ref-type="table"} and [Table S14](#app1-marinedrugs-15-00374){ref-type="app"}; HRESIMS *m/z* 514.8340 \[M + H\]^+^ (calcd. for C~14~H~14~Br~3~O~6~, 514.8335).

**X-ray crystallography.** X-ray crystallographic data were collected on an Oxford Diffraction Gemini CCD diffractometer with Mo-Kα radiation (0.71073 Å) operating within the range 2 \< 2θ \< 50°. The sample was cooled to 190 K with an Oxford Cryosystems Desktop Cooler. Data reduction and empirical absorption corrections were performed using CrysAlisPro (Rigaku Oxford Diffraction, Yarnton, Oxfordshire, UK). The structure was solved by Direct Methods and refined with SHELX \[[@B21-marinedrugs-15-00374]\] and all of the calculations and refinements were carried out by WinGX package \[[@B22-marinedrugs-15-00374]\]. All non-H atoms were refined aniostropically. The thermal ellipsoid plot was produced with ORTEP \[[@B23-marinedrugs-15-00374]\] and the unit cell diagram was drawn with PLATON \[[@B24-marinedrugs-15-00374]\]. Crystallographic data including structure factors in CIF format have been deposited with the Cambridge Crystallographic Data Centre (CCDC 1569026).
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The following are available online at [www.mdpi.com/1660-3397/15/12/374/s1](www.mdpi.com/1660-3397/15/12/374/s1), Isolation Scheme as well as Tabulated 1D and 2D NMR data and spectra for 1--15, X-ray of compound **10**.
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###### 

^1^H NMR Data for Compounds **7a/b**--**9a/b** (600 MHz).

  Position   7a ^a^          7b ^a^          8a ^b^    8b ^b^    9a ^c^         9b ^c^
  ---------- --------------- --------------- --------- --------- -------------- ---------------
  3          3.74, m         3.74, m                             3.50, m        3.50, m
  4a         3.17, m         3.17, m         3.65, s   3.19, s   2.98, dd ^e^   2.976, dd ^e^
  4b         2.490, dd ^d^   2.489, dd ^d^                       2.41, dd ^f^   2.40, dd ^f^
  5-OCH3     3.55, s         3.55, s         3.71, s   3.51, s   3.52, s        3.52, s
  6-OCH3                                                         3.541, s       3.535, s
  7′         7.544, s        7.538, s        4.22, s   4.34, s   7.391, s       7.388, s

^a^ acetone-*d*~6~, ^b^ methanol-*d*~4~, ^c^ DMSO-*d*~6~, ^d^ *J* = 16.8, 7.8 Hz, ^e^ *J* = 16.8, 10.8 Hz, ^f^ *J* = 16.8, 3.0 Hz.

marinedrugs-15-00374-t002_Table 2

###### 

^13^C NMR Data for Compounds **7a/b**--**9a/b** (150 MHz).

  Position   7a ^a^         7b ^a^         8a ^b^        8b ^b^        9a ^c^        9b ^c^
  ---------- -------------- -------------- ------------- ------------- ------------- -------------
  1          167.18, C      167.18, C      170.3, C      166.5, C      166.8, C      166.8, C
  2          135.46, C      135.34, C      145.0, C      144.4, C      133.5, C      133.5, C
  3          41.39, CH      41.37, CH      127.4, C      137.8, C      40.2, CH      40.2, CH
  4          35.40, CH~2~   35.35, CH~2~   35.0, CH~2~   29.5, CH~2~   33.9, CH~2~   33.9, CH~2~
  5          172.80, C      172.76, C      168.7, C      166.8, C      171.5, C      171.5, C
  6          172.54, C      172.49, C      172.4, C      169.0, C      171.5, C      171.5, C
  5-OCH~3~   51.87, CH~3~   51.83, CH~3~   52.8, CH~3~   53.1, CH~3~   52.0, CH~3~   52.0, CH~3~
  6-OCH~3~                                                             51.6, CH~3~   51.6, CH~3~
  1′         129.79, C      129.76, C      128.8, C      127.9, C      128.07, C     128.07, C
  2′         115.38, C      115.23, C      118.9, C      118.4, C      113.9, C      113.9, C
  3′         113.98, C      113.63, C      114.8, C      114.2, C      113.7, C      113.6, C
  4′         144.17, C      144.10, C      146.2, C      145.5, C      143.9, C      143.8, C
  5′         145.36, C      145.32, C      145.6, C      144.8, C      145.2, C      145.0, C
  6′         110.71, C      110.67, C      114.7, C      114.3, C      110.7, C      110.6, C
  7′         141.52, C      141.48, C      41.1, CH      35.9, CH      140.7, C      140.7, C

^a^ acetone-*d*~6~, ^b^ methanol-*d*~4~, ^c^ DMSO-*d*~6~.

marinedrugs-15-00374-t003_Table 3

###### 

^1^H NMR Data for Compounds **10**--**11** (600 MHz).

  Position               10 ^a^ δ~H~, m (J in Hz)   11 ^b^ δ~H~, m (J in Hz)
  ---------------------- -------------------------- --------------------------
  2                      4.98, dd (11.4, 3.0)       4.98, dd (11.4, 3.0)
  4                      6.76, s                    6.73, s
  1-OCH~3~               3.66, s                    3.70, s
  5-OCH~3~               3.44, s                    3.45, s
  6-OC[H]{.ul}~2~CH~3~                              4.26, br q (7.2)
  6-OCH~2~C[H]{.ul}~3~                              1.31, t (7.2)
  7′a                    3.87, dd (14.4, 3.0)       3.81, dd (14.4, 3.0)
  7′b                    3.61, dd (14.4, 11.4)      3.56, dd (14.4, 11.4)

^a^ acetone-*d*~6~, ^b^ methanol-*d*~4~.

marinedrugs-15-00374-t004_Table 4

###### 

^1^H NMR Data for Compounds **12**--**15** (600 MHz).

  Position   12 ^a^ δ~H~, m (*J* in Hz)   13 ^b^ δ~H~, m (*J* in Hz)   14 ^b^ δ~H~, m (*J* in Hz)   15 ^a^ δ~H~, m (*J* in Hz)
  ---------- ---------------------------- ---------------------------- ---------------------------- ----------------------------
  2a         6.79, br t (6.6)             3.35, m                      3.75, dd (9.0, 6.0^)^        3.79, dd (9.6, 5.4)
  2b                                      3.27, dd (20.4, 7.8)                                      
  3                                       3.34, m                                                   
  4a         3.60, br s                   2.86, dd (17.4, 7.2)         6.22. d (1.2)                6.17, d (1.2)
  4b                                      2.73, dd (17.4, 6.0)         5.44, br s                   5.52, s
  1-OCH~3~                                                             3.64, s                      3.62, s
  5-OCH~3~   3.66, s                      3.68, s                                                   
  6-OCH~3~                                3.71, s                                                   3.71, s
  7′a        4.05, s                                                   3.65, dd (13.8, 6.0)         3.69, dd (14.4, 5.4)
  7′b                                                                  3.54, dd (13.8, 9.0)         3.56, dd (14.4, 9.6)

^a^ acetone-*d*~6~, ^b^ methanol-*d*~4~.

marinedrugs-15-00374-t005_Table 5

###### 

^13^C NMR Data for Compounds **10**--**15** (150 MHz).

  Position               10 ^a^ δ~C~, Type   11 ^b^ δ~C~, Type   12 ^a^ δ~C~, Type   13 ^b^ δ~C~, Type   14 ^b^ δ~C~, Type   15 ^a^ δ~C~, Type
  ---------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  1                      171.9, C            173.5, C                                                    174.5, C            172.4, C
  2                      43.0, C             43.7, C             141.3, C            44.9, CH~2~         48.8, CH            48.2, CH
  3                      142.4, C            142.4, C            128.1, C            37.4, CH            139.3, C            138.3, C
  4                      130.5, CH           131.3, CH           33.2, CH~2~         35.6, CH~2~         129.1, CH~2~        128.7, CH~2~
  5                      165.8, C            166.7, C            171.3, C            173.9, C                                
  6                      167.0, C            167.0, C            167.9, C            175.5, C            169.2, C            166.6, C
  1-OCH~3~               52.3, CH~3~         52.9, CH~3~                                                 52.8, CH~3~         52.3, CH~3~
  5-OCH~3~               52.1, CH~3~         52.5, CH~3~         52.0, CH~3~         52.5, CH~3~                             
  6-OCH~3~                                                                           52.8, CH~3~                             52.3, CH~3~
  6-O[C]{.ul}H~2~CH~3~                       63.2, C                                                                         
  6-OCH~2~[C]{.ul}H~3~                       14.5, CH~3~                                                                     
  1′                     130.7, C            130.6, C            131.0, C            136.1, C            131.4, C            131.3, C
  2′                     118.5, C            118.8, C            117.3, C            114.5, C            118.3, C            118.0, C
  3′                     113.7, C            114.4, C            114.0, C            110.5, C            114.5, C            113.9, C
  4′                     144.1, C            145.1, C            144.4, C            147.3, C            145.0, C            144.0, C
  5′                     143.8, C            144.8, C            144.3, C            145.3, C            144.8, C            143.9, C
  6′                     114.3, C            114.8, C            113.0, C            106.3, C            114.3, C            113.8, C
  7′                     39.0, CH~2~         39.4, CH~2~         39.0, CH~2~         202.2, C            39.4, CH~2~         39.1, CH~2~

^a^ acetone-*d*~6~, ^b^ methanol-*d*~4~.
